title: Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults.
abstract: Pertussis-specific antibody and cell-mediated immune (CMI) responses were studied in adults 8 years after booster immunization with either a bicomponent (pertussis toxin and filamentous hemagglutinin) or a monocomponent (pertactin) acellular vaccine and in age-matched healthy controls. The levels of vaccine-induced antibodies were also compared between the serum samples collected before, 1 month, 4 years, and 8 years after immunization. Over the follow-up period, geometric mean values (GMV) of antibodies to the vaccine antigens decreased in both groups of vaccinees. However, the 8-year postimmunization GMV were 3-20 times higher than preimmunization GMV (all P values <0.01). Moreover, both antibody and CMI responses to the vaccine antigens were significantly higher in the vaccinees than in the controls (all P<0.01 for antibody; all P<0.001 for CMI responses). The results show that antibody and CMI responses induced by acellular pertussis vaccines can persist for up to 8 years after booster immunization of adults primed with whole-cell vaccine.
authors.affiliation: National Public Health Institute, Department in Turku, Kiinamyllynkatu 13, Fin-20520, Turku, Finland. tranminh@utu.fi
authors.forename: N N
authors.initials: NN
authors.lastname: Tran Minh
authors.forename: Q
authors.initials: Q
authors.lastname: He
authors.forename: K
authors.initials: K
authors.lastname: Edelman
authors.forename: A
authors.initials: A
authors.lastname: Putto-Laurila
authors.forename: H
authors.initials: H
authors.lastname: Arvilommi
authors.forename: M K
authors.initials: MK
authors.lastname: Viljanen
authors.forename: J
authors.initials: J
authors.lastname: Mertsola
mesh_terms: D018829:Adhesins, Bacterial / Q000008:administration & dosage / Q000276:immunology; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage / Q000276:immunology; D001886:Bordetella pertussis / Q000276:immunology*; D016022:Case-Control Studies; D005260:Female; D006388:Hemagglutinins / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D008297:Male; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology*; D013997:Time Factors; D010566:Virulence Factors, Bordetella / Q000008:administration & dosage / Q000276:immunology
chemical_list: D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D006388:Hemagglutinins; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella; C065273:filamentous hemagglutinin adhesin, Bordetella pertussis; C068929:pertactin; D037342:Pertussis Toxin